This study is for patients that have a tumor that cannot be removed through surgery (unresectable) or may have spread (metastasized) to other parts of their body. In this study, ASP1951 will be given alone (monotherapy) or combined with pembrolizumab (combination therapy). Both ASP1951 and pembrolizumab will be considered study drug. Pembrolizumab has been approved by FDA for use in patients with skin, lung, cervical cancer, certain cancers of head and neck and other cancers but may not be approved to treat all types of cancer. However, the use of ASP1951 plus pembrolizumab has not been approved by regulatory authorities and is therefore investigational. The study consists of 3 periods: screening (up to 28 days), treatment (up to 48 weeks [16 cycles]) and follow up (up to 45 weeks), followed by an optional re-treatment period for participants that qualify. The re-treatment period will allow participants to receive study drug treatment again for up to 16 additional cycles (approximately 48 weeks), for a maximum total treatment and re-treatment period of 32 cycles (approximately 96 weeks). Both study drugs are administered intravenously (into the vein).This is the first time the investigational study drug ASP1951 is being tested in humans; however, studies in animals showed that the study drug is safe to be tested in humans.
This study is for patient that have been diagnosed with high-risk locally advanced cervical cancer. High-risk locally advanced cervical cancer includes participants who have Stage IB2-IIB disease with pelvic or para-aortic lymph node involvement or more advanced stages of locally advanced cervical cancer. The purpose of this study is to test the safety of the study drug, pembrolizumab, when given with chemoradiotherapy and to see how it works when given with chemotherapy and compares to treatment with chemotherapy alone. Participants can expect to be treated with study drugs for about 2 years.
This study is for women with endometrial cancer. The purpose is to find out if adding a new immunotherapy drug to the usual combination of chemotherapy drugs can lower the chance of your endometrial cancer growing or spreading.
This is a research study to find out if the study drug (ASP1948 or ASP1948 plus nivolumab or pembrolizumab) is safe and to determine the safest, most effective dose of the drug. When the safe dose is identified, it will be used to evaluate if the study treatment causes tumors to shrink in patients. During this study, the study drug will be continuously assessed to determine if it is safe and tolerated by patients taking it. The following adverse events have been reported in more than 10% of patients: fatigue, abdominal pain, decreased appetite, back pain, dyspnea (difficulty breathing), hyponatraemia (low sodium levels), anemia (low red cell count), and constipation. Since these events may occur in patients not taking ASP1948 and since there have been no clinical trials comparing patients taking ASP1948 with those not taking ASP1948, it is difficult to know at this time whether they were caused by ASP1948.
This study is for women who have ovarian cancer, fallopian tube cancer or primary peritoneal cancer which has grown or recurred. The purpose of this study is to compare any good and bad effects of adding Atezolizumab to the usual chemotherapy (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab. Atezolizumab is a PD-L1 inhibitor that may allow the immune system to recognize and destroy tumor cells.
This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.
The objectives of this trial are to find out whether adjuvant chemotherapy (using two other drugs) after chemo-radiation will increase the chances of survival and reduce the risk of tumor recurrence in the pelvis and other places. The risk and severity of side effects and quality of life during and after treatment will also be evaluated and compared. This trial will help the researchers understand the safety and effectiveness of this new treatment regimen for cervical cancer.